Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Goldman Sachs Reiterates Buy on Incyte (INCY)
June 22, 2018 7:30 AM EDTGoldman Sachs reiterated a Buy rating and $97.00 price target on Incyte (NASDAQ: INCY) following the company's investor event. INCY showcased its five product late-stage portfolio in development for 15 indications.
INCY continues to advance multiple clinical development programs for patients with myeloproliferative... More
